Nicholas Blondin, MD

• Aladine Elsamadicy
• Anita Huttner
• Benjamin L. Judson
• Joseph Paul Antonios
• Joseph Piepmeier
• Joseph Schindler
• Kanat Yalcin
• Ketu Mishra-Gorur
• Murat Gunel
• Robert Fulbright
• Robin de Graaf
• Sacit Bulent Omay
• Tanyeri Barak
• Veronica Chiang
• Zeynep Erson Omay

Nervous System Neoplasms; Neurology

• SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPYKumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Sweed N, Dugan M, Kesari S. SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY. Neuro-Oncology Advances 2023, 5: iii20-iii20. PMCID: PMC10402348, DOI: 10.1093/noajnl/vdad070.077.
• NEIM-11 DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMASKim L, De Feyter H, de Graaf R, Fulbright R, Liu Y, Rothman D, Baehring J, Blondin N, Kim P, Antonio O, Chiang V, Moliterno J, Omay S, Piepmeier J, Corbin Z. NEIM-11 DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMAS. Neuro-Oncology Advances 2023, 5: iii16-iii16. PMCID: PMC10402410, DOI: 10.1093/noajnl/vdad070.060.
• An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastomaBarkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic J, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology 2023, 12: cns102. PMID: 37462385, PMCID: PMC10410686, DOI: 10.2217/cns-2022-0016.
• The clinical and genomic features of seizures in meningiomasDincer A, Jalal M, Gupte T, Vetsa S, Vasandani S, Yalcin K, Marianayagam N, Blondin N, Corbin Z, McGuone D, Fulbright R, Erson-Omay Z, Günel M, Moliterno J. The clinical and genomic features of seizures in meningiomas. Neuro-Oncology Advances 2023, 5: i49-i57. PMID: 37287582, PMCID: PMC10243847, DOI: 10.1093/noajnl/vdac110.
• Abstract CT062: GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastomaMellinghoff I, Alexander B, Berry D, Blondin N, Buxton M, Cavenee W, Colman H, de Groot J, de la Fuente M, Ellingson B, Gordon G, Hyddmark E, Khasraw M, Lassman A, Lee E, Li W, Lim M, Mikkelsen T, Nelli A, Perry J, Sulman E, Tanner K, Weller M, Wen P, Cloughesy T. Abstract CT062: GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. Cancer Research 2023, 83: ct062-ct062. DOI: 10.1158/1538-7445.am2023-ct062.
• NIMG-105. DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMASKim L, De Feyter H, de Graaf R, Fulbright R, Liu Y, Rothman D, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Corbin Z. NIMG-105. DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMAS. Neuro-Oncology 2022, 24: vii189-vii189. PMCID: PMC9660955, DOI: 10.1093/neuonc/noac209.723.
• BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASISKumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Sharma A, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Matsutani M, Sales E, Sweed N, Dugan M, Kesari S. BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASIS. Neuro-Oncology 2022, 24: vii4-vii5. DOI: 10.1093/neuonc/noac209.015.
• TRAF7 Mutated Subgroups Differ in Sphenoid Wing Meningiomas with HyperostosisJin L, Vetsa S, Vasandani S, Nadar A, Youngblood M, Gupte T, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Gorelick E, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, Marianayagam N, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. TRAF7 Mutated Subgroups Differ in Sphenoid Wing Meningiomas with Hyperostosis. Journal Of Neurological Surgery Part B Skull Base 2022, 83: s1-s270. DOI: 10.1055/s-0042-1743640.
• QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTSBlondin N. QOLP-03. OBSERVATIONS OF COMPLEMENTARY CANNABIS THERAPY IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2021, 23: vi183-vi183. PMCID: PMC8598802, DOI: 10.1093/neuonc/noab196.724.
• INNV-37. XCELSIOR: A REAL-TIME, REAL-WORLD LEARNING PLATFORM FOR PATIENTS WITH ADVANCED CANCERStuhlmiller T, Shapiro M, Wasserman A, Osking Z, Shrager J, Federowicz B, Warner M, Friedland J, Musella A, Blondin N, Fonkem E, Wong E, Kesari S. INNV-37. XCELSIOR: A REAL-TIME, REAL-WORLD LEARNING PLATFORM FOR PATIENTS WITH ADVANCED CANCER. Neuro-Oncology 2021, 23: vi113-vi113. DOI: 10.1093/neuonc/noab196.448.
• INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMABlondin N, Fulbright R, Huttner A, Moliterno-Gunel J. INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA. Neuro-Oncology 2021, 23: vi106-vi106. DOI: 10.1093/neuonc/noab196.419.
• BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCERKumthekar P, Blouw B, Mayer J, Fisher D, Dugan M, Azadi A, Blondin N. BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER. Neuro-Oncology 2021, 23: vi10-vi10. PMCID: PMC8598619, DOI: 10.1093/neuonc/noab196.036.
• NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMASJin L, Youngblood M, Gupte T, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS. Neuro-Oncology 2021, 23: vi144-vi144. PMCID: PMC8598770, DOI: 10.1093/neuonc/noab196.562.
• INNV-09. SURGICAL STRATEGIES FOR OLDER PATIENTS WITH GLIOBLASTOMABarak T, Hwang L, Chen J, Jin L, Miyagishima D, Yalcin K, Ogilvie S, Antonios J, Theriault B, Huttner A, McGuone D, Lifton N, Blondin N, Corbin Z, Zhang Y, Gunel M, Erson-Omay Z, Fulbright R, Tabar T, Moliterno-Gunel J. INNV-09. SURGICAL STRATEGIES FOR OLDER PATIENTS WITH GLIOBLASTOMA. Neuro-Oncology 2021, 23: vi107-vi107. PMCID: PMC8598632, DOI: 10.1093/neuonc/noab196.421.
• Surgical strategies for older patients with glioblastomaBarak T, Vetsa S, Nadar A, Jin L, Gupte TP, Fomchenko EI, Miyagishima DF, Yalcin K, Vasandani S, Gorelick E, Zhao AY, Antonios J, Theriault BC, Lifton N, Marianayagam N, Omay B, Omay ZE, Huttner A, McGuone D, Blondin NA, Corbin Z, Fulbright RK, Moliterno J. Surgical strategies for older patients with glioblastoma. Journal Of Neuro-Oncology 2021, 155: 255-264. PMID: 34626296, PMCID: PMC8651607, DOI: 10.1007/s11060-021-03862-z.
• Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomasJin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J. Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas. Journal Of Neuro-Oncology 2021, 154: 237-246. PMID: 34350560, DOI: 10.1007/s11060-021-03819-2.
• Hypermutated phenotype in gliosarcoma of the spinal cordHong CS, Kuzmik GA, Kundishora AJ, Elsamadicy AA, Koo AB, McGuone D, Blondin NA, DiLuna ML, Erson-Omay EZ. Hypermutated phenotype in gliosarcoma of the spinal cord. Npj Precision Oncology 2021, 5: 8. PMID: 33580181, PMCID: PMC7881101, DOI: 10.1038/s41698-021-00143-w.
• Clinical and genomic factors associated with seizures in meningiomas.Gupte TP, Li C, Jin L, Yalcin K, Youngblood MW, Miyagishima DF, Mishra-Gorur K, Zhao AY, Antonios J, Huttner A, McGuone D, Blondin NA, Contessa JN, Zhang Y, Fulbright RK, Gunel M, Erson-Omay Z, Moliterno J. Clinical and genomic factors associated with seizures in meningiomas. Journal Of Neurosurgery 2020, 135: 835-844. PMID: 33276341, DOI: 10.3171/2020.7.jns201042.
• INNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS.Reddy N, Blondin N. INNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS. Neuro-Oncology 2019, 21: vi135-vi135. PMCID: PMC6847258, DOI: 10.1093/neuonc/noz175.566.
• ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMABarkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.
• ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. ACTR-68. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847970, DOI: 10.1093/neuonc/noz175.109.
• Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastomaKelly J, Proescholdt C, Blondin N. Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastoma. Cancer Research 2019, 79: lb-163-lb-163. DOI: 10.1158/1538-7445.am2019-lb-163.
• Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastomaKelly J, Proescholdt C, Blondin N. Abstract LB-163: Comparing clinical value scores (NCCN, ASCO and ESMO) for TTFields treatment in glioblastoma. 2019, lb-163-lb-163. DOI: 10.1158/1538-7445.sabcs18-lb-163.
• Treatment of Cerebral Cysts with Ommaya Reservoir – A Review of 4 Cases (P1.6-029)Mayers M, Blondin N. Treatment of Cerebral Cysts with Ommaya Reservoir – A Review of 4 Cases (P1.6-029). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p1.6-029.
• QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENTBlondin N. QOLP-04. THE EVOLVING ROLE OF COMPLEMENTARY CANNABIS THERAPY IN GLIOBLASTOMA TREATMENT. Neuro-Oncology 2018, 20: vi214-vi215. PMCID: PMC6217477, DOI: 10.1093/neuonc/noy148.890.
• HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVALBlondin N, Proescholdt C, Kelly J. HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL. Neuro-Oncology 2018, 20: vi119-vi119. PMCID: PMC6217248, DOI: 10.1093/neuonc/noy148.495.
• ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.
• CMET-07. VISMODEGIB TREATMENT OF INTRACRANIAL INVASION OF BASAL CELL CARCINOMAJameyfield E, Blondin N. CMET-07. VISMODEGIB TREATMENT OF INTRACRANIAL INVASION OF BASAL CELL CARCINOMA. Neuro-Oncology 2017, 19: vi40-vi40. PMCID: PMC5691966, DOI: 10.1093/neuonc/nox168.156.
• Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancementConnelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer 2016, 16: 842. PMID: 27809808, PMCID: PMC5096303, DOI: 10.1186/s12885-016-2890-0.
• ATCT-06MANAGEMENT OF GLIOMATOSIS CEREBRI WITH TEMOZOLOMIDE AND TUMOR TREATING FIELDSBlondin N. ATCT-06MANAGEMENT OF GLIOMATOSIS CEREBRI WITH TEMOZOLOMIDE AND TUMOR TREATING FIELDS. Neuro-Oncology 2015, 17: v2-v2. PMCID: PMC4638557, DOI: 10.1093/neuonc/nov206.06.
• MPTH-03IMPLEMENTATION AND UTILIZATION OF GENOMIC PROFILING IN A COMMUNITY NEURO-ONCOLOGY PRACTICEBlondin N. MPTH-03IMPLEMENTATION AND UTILIZATION OF GENOMIC PROFILING IN A COMMUNITY NEURO-ONCOLOGY PRACTICE. Neuro-Oncology 2015, 17: v138-v138. PMCID: PMC4638974, DOI: 10.1093/neuonc/nov222.03.
• Primary CNS LymphomaBlondin N, Baehring J, Hochberg F. Primary CNS Lymphoma. 2014, 308-315. DOI: 10.1002/9781118589199.ch48.
• Diagnosis and management of periodic hypothermiaBlondin NA. Diagnosis and management of periodic hypothermia. Neurology Clinical Practice 2014, 4: 26-33. PMID: 29473588, PMCID: PMC5765588, DOI: 10.1212/01.cpj.0000437350.47610.3a.
• Anaplastic Gliomas Radiation, Chemotherapy, or Both?Blondin NA, Becker KP. Anaplastic Gliomas Radiation, Chemotherapy, or Both? Hematology/Oncology Clinics Of North America 2012, 26: 811-823. PMID: 22794285, DOI: 10.1016/j.hoc.2012.04.003.
• Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (P07.148)Blondin N, Vortmeyer A, Tokuno H. Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (P07.148). Neurology 2012, 78: p07.148-p07.148. DOI: 10.1212/wnl.78.1_meetingabstracts.p07.148.
• Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (IN7-1.009)Blondin N, Vortmeyer A, Tokuno H. Maternally Inherited Diabetes and Deafness (MIDD) Syndrome Associated with Myoclonus (IN7-1.009). Neurology 2012, 78: in7-1.009-in7-1.009. DOI: 10.1212/wnl.78.1_meetingabstracts.in7-1.009.
• Plantar Flexion with Noxious Dorsal Foot Stimulation in Brain DeathHernandez AL, Blondin NA, Curiale G, Greer DM. Plantar Flexion with Noxious Dorsal Foot Stimulation in Brain Death. Neurocritical Care 2012, 17: 268-270. PMID: 22528275, DOI: 10.1007/s12028-012-9697-x.
• Paraneoplastic Syndrome of Inappropriate Antidiuretic Hormone Mimicking Limbic EncephalitisBlondin NA, Vortmeyer AO, Harel NY. Paraneoplastic Syndrome of Inappropriate Antidiuretic Hormone Mimicking Limbic Encephalitis. JAMA Neurology 2011, 68: 1591-1594. PMID: 22159058, DOI: 10.1001/archneurol.2011.876.
• Unilateral Tongue Atrophy and FasciculationBlondin NA, Huttner A, Baehring JM. Unilateral Tongue Atrophy and Fasciculation. JAMA Neurology 2011, 68: 1478-1478. PMID: 22084136, DOI: 10.1001/archneurol.2011.652.
• First-order Horner syndrome due to ipsilateral thalamic hemorrhageSawires M, Berek K, Blondin N, Schindler J. First-order Horner syndrome due to ipsilateral thalamic hemorrhage. Neurology 2011, 77: 1019. PMID: 21893675, DOI: 10.1212/wnl.0b013e31822470d4.
• Neurologic Prognosis in Cardiac Arrest Patients Treated With Therapeutic HypothermiaBlondin NA, Greer DM. Neurologic Prognosis in Cardiac Arrest Patients Treated With Therapeutic Hypothermia. The Neurologist 2011, 17: 241-248. PMID: 21881465, DOI: 10.1097/nrl.0b013e318224ee0e.
• Teaching NeuroImages: First-order Horner syndrome due to ipsilateral thalamic hemorrhageBlondin NA, Schindler JL. Teaching NeuroImages: First-order Horner syndrome due to ipsilateral thalamic hemorrhage. Neurology 2011, 76: e14. PMID: 21263131, DOI: 10.1212/wnl.0b013e31820882db.
• Thrombolysis in Right versus Left Hemispheric StrokeBlondin NA, Staff I, Lee N, McCullough LD. Thrombolysis in Right versus Left Hemispheric Stroke. Journal Of Stroke And Cerebrovascular Diseases 2010, 19: 269-272. PMID: 20471856, DOI: 10.1016/j.jstrokecerebrovasdis.2009.04.012.
• A case of lamotrigine-associated anticonvulsant hypersensitivity syndrome.Blondin NA, Zahedi S, Hale MS. A case of lamotrigine-associated anticonvulsant hypersensitivity syndrome. The Primary Care Companion For CNS Disorders 2008, 10: 249-50. PMID: 18615175, PMCID: PMC2446496, DOI: 10.4088/pcc.v10n0312b.
• Rules of engagement promote polarity in RNA traffickingCarson JH, Blondin N, Korza G. Rules of engagement promote polarity in RNA trafficking. BMC Neuroscience 2006, 7: s3. PMID: 17118157, PMCID: PMC1775043, DOI: 10.1186/1471-2202-7-s1-s3.